Corticosteroids in the Early Treatment of Covid-19: Feasibility Study of the Use of Czech Administrative Data in an Real-World Outcomes Evaluation
- Resource Type
- Conference
- Authors
- Donin, Gleb; Tichopad, Ales
- Source
- 2022 E-Health and Bioengineering Conference (EHB) E-Health and Bioengineering Conference (EHB), 2022. :01-04 Nov, 2022
- Subject
- Bioengineering
Communication, Networking and Broadcast Technologies
Components, Circuits, Devices and Systems
Computing and Processing
Engineered Materials, Dielectrics and Plasmas
Fields, Waves and Electromagnetics
Signal Processing and Analysis
COVID-19
Antibiotics
Insurance
Companies
Regression analysis
Indexes
History
real world evidence
corticosteroids
administrative claims data
- Language
- ISSN
- 2575-5145
In this study, we used administrative data of six health insurance companies in the Czech Republic, to analyse the incidence of hospitalization in COVID-19 patients early treated with corticosteroids (CS). Cohort selection was based on index date defined by the date of the PCR test reported with COVID-19-related ICD-10 diagnoses found within a period of March 2020 - November 2020. The CS treated cohort was defined patients treated with CS within the 7 days after index date with no history of antibiotics nor corticosteroids within 30 days before index date. The control groups were defined either with or without a use of codeine within the 7 days after index date but always with no use of antibiotics nor corticosteroids within 30 days before and within the 7 days after index date. In total 590 274 records fulfilled the inclusion criteria, of whom 3 670 (0.62%) were hospitalized and 2 467 (0.42 % ) used CS within 7 days after ID. The contrast between a studied medication and a control was analysed with the logistic regression analysis with adjustment on age. Treatment with CS as compared with a cohort of patients with no curative treatment was associated with significantly (Chi square test p